Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

Core Viewpoint - Nanobiotix (NBTX) shares increased approximately 13% in pre-market trading following the initiation of dosing in a mid-stage study for JNJ-1900, a potential first-in-class radioenhancer for lung cancer treatment, in collaboration with Johnson & Johnson [1][2] Company Developments - The first patient has been dosed in the phase II CONVERGE study targeting Stage 3 unresectable non-small cell lung cancer (NSCLC), with eligibility criteria including patients receiving standard chemoradiation followed by AstraZeneca's Imfinzi [2] - Nanobiotix's pipeline currently includes only JNJ-1900, which is being evaluated for multiple solid tumor indications, both as a single agent and in combination with anti-PD-1 immune checkpoint inhibitors [4] - The candidate is also being assessed in a registrational phase III NANORAY-312 study for locally advanced head and neck squamous cell cancers, with Fast Track designation from the FDA [5] Recent Study Results - An early-stage study for JNJ-1900 in locally advanced pancreatic cancer showed a median overall survival of 23 months in treated patients, compared to 19.2 months based on historical data, indicating promising results [6][7] - Following positive outcomes, a new study cohort has been launched to evaluate JNJ-1900 in combination with standard chemoradiation for pancreatic cancer, with enrollment currently ongoing [7] Market Performance - Over the past three months, NBTX shares have decreased by 40.2%, contrasting with a 10.6% decline in the industry [3]